Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.
Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:
- Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
- Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
- Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.
In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.
Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.
Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.
Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
-
Rhea-AI Summary
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., has been named to Forbes list of Canada’s Best Employers 2024, ranking No. 1 of Drugs & Biotechnology employers and No. 28 of 300 overall employers. Forbes and Statista Inc. conducted independent surveys of over 40,000 Canada-based employees from companies employing at least 500 people in all industry sectors, with over 900,000 employer evaluations considered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. reported a 7% increase in local currency terms for 2023 revenues of $15.8 billion compared to 2022. AUSTEDO® exceeded $1.2 billion in annual revenues, up 28% from 2022. The company expects strong growth to continue in 2024 with expected revenues of ~$1.5 billion. AJOVY® had global annual revenues of $435 million, up 16% from 2022. The generics business stabilized, with back-to-revenue growth in Q4 2023. The ongoing net debt reduction reduced to $16.6 billion as of December 31, 2023. The company's pivot to growth strategy is in action, with Teva api intended divestiture to focus on core business strengths and capital allocation towards growth engines and innovation. The company also entered into exclusive collaborations with Sanofi and Royalty Pharma, and a license agreement with Biolojic Design for potential treatments of Atopic Dermatitis and Asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
Rhea-AI Summary
Teva announced its intention to divest its active-pharmaceutical ingredient (API) business, or 'TAPI', to focus on core business strengths, capital allocation towards growth and innovation, and better serve patients. The divestiture is expected to enhance TAPI's position as a global leader in the growing API market and create additional value for Teva’s shareholders and stakeholders. The intended divestiture is expected to be completed in the first half of 2025, subject to reaching a satisfactory agreement on transaction terms with a prospective purchaser and the approval of an agreed transaction by Teva’s Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will release its fourth quarter and full year 2023 financial results and financial guidance for 2024 on January 31, 2024. A conference call and live webcast will follow the release at 8:00 a.m. ET. Participants can register in advance for the call and access the webcast on Teva's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces CEO's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (TEVA) and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. BD9, a dual specific antibody, has the potential to target IL-13 / TSLP and treat inflammatory diseases such as atopic dermatitis and asthma. This collaboration supports Teva's Pivot to Growth strategy and aims to enhance the company's early-stage pipeline through strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (TEVA) reports that a post hoc analysis of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. The analysis compared the safety and efficacy of fremanezumab migraine preventive treatment in obese migraine patients vs normal weight migraine patients for a period of 6 months. After 6 months of treatment, monthly migraine days in migraine patients with high BMI was reduced to 6.8 vs 7.2 for normal weight patients. Adverse events in patients with obesity were similar to non-obese patients treated with fremanezumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
-
Rhea-AI Summary
Teva Pharmaceuticals (TEVA) closes collaboration deal with Sanofi (SAN, SNY) to co-develop and co-commercialize asset TEV '574, currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease. Teva to receive $500 million upfront payment and up to $1 billion in milestones. Joint development and profit sharing agreement with Sanofi. Estimated 10 million people worldwide live with IBD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) to present at Evercore ISI HealthCONx Conference on November 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
FAQ
What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?
The current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is $17.12 as of November 22, 2024.
What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?
The market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is approximately 19.2B.
What does Teva Pharmaceutical Industries Limited specialize in?
Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.
Where is Teva headquartered?
Teva is headquartered in Tel Aviv, Israel.
What are some of Teva's key products?
Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.
In which regions does Teva operate?
Teva operates in North America, Europe, Japan, Russia, and Israel.
How much of Teva's sales come from North America?
Approximately 50% of Teva's sales come from North America.
What therapeutic areas does Teva focus on?
Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.
What is Anda?
Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.
Does Teva offer contract manufacturing services?
Yes, Teva offers contract manufacturing services.
What role does Teva play in the U.S. generic prescription market?
Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.
What recent advancements has Teva made?
Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.
Teva Pharmaceutical Industries Limited American Depositary Shares
NYSE:TEVA
TEVA Rankings
TEVA Stock Data
19.22B
1.13B
0%
57.25%
1.6%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States of America
TEL AVIV